Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma by Yoo, Changhoon et al.
Modified Number of Extranodal Involved Sites as a
Prognosticator in R-CHOP-Treated Patients with
Disseminated Diffuse Large B-Cell Lymphoma
Changhoon Yoo
1, Shin Kim
2, Byeong Seok Sohn
2, Jeong-Eun Kim
1, Dok Hyun Yoon
2, Jooryung Huh
3, Dae Ho Lee
2,
Sang-We Kim
2, Jung-Shin Lee
2, and Cheolwon Suh
2
Departments of 1Internal Medicine, 2Oncology and 3Pathology, Asan Medical Center, University of Ulsan College of
Medicine, Seoul, Korea
DOI: 10.3904/kjim.2010.25.3.301
ORIGINAL ARTICLE
Background/Aims: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy
(R-CHOP) has improved survival in patients with diffuse large B-cell lymphoma (DLBCL) and weakened the
prognostic power of the international prognostic index (IPI). We evaluated the efficacy of the IPI and revised IPI
(R-IPI) in patients with DLBCL who were treated with R-CHOP, focusing on extranodal site number (ENS)
because extranodal involvement occurs frequently in Koreans.  
Methods: A total of 126 R-CHOP-treated patients with stage III/IV DLBCL were analyzed. We performed a
retrospective analysis of the clinicopathologic factors and verified the predictive power of the standard IPI and R-
IPI. Various numbers of extranodal sites were analyzed for further stratification, and we set the extranodal site-
modified IPI (E-IPI) as the IPI when the number of extranodal sites was stratified as < 3 vs. ≥ 3.  
Results: A univariate analysis showed that ENS was associated with complete response (CR, p = 0.04), event-
free survival (EFS, p = 0.01), and overall survival (OS, p < 0.001) when the ENS cut-off was set at ≥ 3. A
multivariate analysis revealed that an ENS ≥ 3 remained associated with EFS (p < 0.01; hazard ratio [HR], 2.60;
95% confidence interval [CI], 1.29 to 5.26) and OS (p < 0.01; HR, 3.52; 95% CI, 1.68 to 7.35). The IPI was
effective for determining prognosis in terms of OS (p = 0.04) but not EFS (p = 0.17). The R-IPI was effective in
terms of both variables (p = 0.02 and 0.04, respectively), as was the E-IPI (p = 0.01 and 0.001, respectively).  
Conclusions: An ENS < 3 vs. ≥ 3, rather than the original < 2 vs. ≥ 2, was the most significant prognostic factor
for EFS and OS. All three indices were predictive, but only the E-IPI identified the high-risk group of R-CHOP-
treated Korean patients with disseminated DLBCL. (Korean J Intern Med 2010;25:301-308)
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INTRODUCTION
After cyclophosphamide, doxorubicin, vincristine, and
prednisone (CHOP) chemotherapy was introduced in the
1970s, it became the standard treatment regimen for
patients with diffuse large B-cell lymphoma (DLBCL).
More intensive regimens were designed subsequently, but
did not lead to additional survival benefits [1]. However,
when rituximab was developed and combined with CHOP
chemotherapy (R-CHOP), the survival of patients with
DLBCL was dramatically improved [2-4].
DLBCL is characterized by a variety of clinical features,
and the prognosis of this disease varies depending on
these features. Because high-risk patients may benefit
from alternative or intensive strategies, it is important to
classify patients with DLBCL by their prognosis. For thispurpose, many clinical factors and biomarkers have been
evaluated and suggested as prognostic factors [5]. This led
to the international prognostic index (IPI), which is based
on five clinical factors; age > 60 years, stage III/IV disease,
> 1 extranodal site, European Cooperative Oncology
Group (ECOG) performance status ≥ 2, and elevated
serum lactate dehydrogenase (LDH) levels [6]. Until
recently, the IPI was the standard indicator that was
generally used in practice and clinical trials to predict
patient outcomes [6]. 
Korean patients with DLBCL have extranodal involve-
ment much more frequently than patients in other
countries do (50 to 60% vs. about 30%) [7-11]. This more
prevalent extranodal involvement suggests that, for
Koreans, the cut-off number of extranodal sites indicating
a poor prognosis should be higher than the cut-off applied
in the IPI (≥ 2). However, systematic studies examining
this issue have not been performed.
Furthermore, several reports have shown that R-CHOP
chemotherapy overcomes factors that were found previously
to indicate a poor prognosis, which means that the standard
IPI has become less effective for predicting the outcomes
of R-CHOP-treated patients [2,12-15]. The widespread use
of R-CHOP indicates that the hitherto widely accepted
DLBCL prognostic factors should be reevaluated. Indeed,
a number of recent studies have sought to identify new
factors that allow a more effective determination of the
prognosis of DLCLB patients [12,14,16]. One of these, a
study in British Columbia, showed that the revised IPI (R-
IPI) is a better indicator of prognosis than the standard
IPI for R-CHOP-treated patients with DLBCL [15]. In the
R-IPI, patients are classified with a very good, good, or
poor prognosis depending on whether they have 0, 1 to 2,
or 3 to 5 IPI factors, respectively [15]. The superior prognostic
effectiveness of R-IPI was recently confirmed by a
subsequent study [14]. 
Here, we performed a retrospective analysis to define
prognostic factors for R-CHOP-treated patients with
DLBCL in Korea. In particular, we sought to identify the
appropriate extranodal site cut-off number that maximizes
the prognostic significance of this factor for the Korean
population. We also assessed the predictive power of the
standard IPI, the R-IPI, and a modified form of the IPI (E-
IPI) in which the extranodal site number cut-off was set at
≥ 3.
METHODS
Patients
We searched the Asan Medical Center (Seoul, Korea)
lymphoma database and identified newly diagnosed
patients with stage III/IV CD20+ DLBCL, who were
treated with R-CHOP as first-line chemotherapy. In total,
126 patients who were diagnosed from January 2002 to
May 2008 were included in this retrospective analysis. All
pathology records were reviewed by a hematopathologist
(JH) and classified according to the WHO classification
system. The clinical and demographic data were collected
by reviewing the patients’ medical records. 
A staging evaluation was performed according to the
Ann Arbor staging system. This involved performing a
physical examination, determining complete blood counts
and differential white blood cell counts, assessing the
biochemical profile (including LDH levels), and performing
a bilateral bone marrow aspiration and biopsy, a computed
tomography (CT) scan of the neck, thorax, abdomen and
pelvis, and whole-body positron emission tomography. 
IPI factors were identified from the clinical data according
to a previous report [6]. The patients were then assigned
to standard IPI groups, which consisted of low-risk (1 IPI
factor), intermediate-risk (2 to 3 IPI factors), and high-
risk (4 to 5 IPI factors) groups. In a separate analysis, the
patients were divided into R-IPI groups, which consisted
of good- (1 to 2 IPI factors) and poor-prognosis (3 to 5 IPI
factors) groups [15]. As this study involved only stage III
and IV patients, all patients included in this analysis had
at least one IPI factor. Consequently, none of the patients
fell into the very good-prognosis group (0 IPI factors).
All patients were treated with R-CHOP and were
intended to receive six to eight cycles of chemotherapy.
Rituximab (375 mg/m2) was administered at 3-week
intervals with the standard dose of CHOP. 
Statistical analysis
The primary outcomes of this study were complete
response (CR), event-free survival (EFS), and overall survival
(OS). CR was determined according to the conventional
response criteria [17]. EFS was estimated from the date of
initial chemotherapy to the date of disease progression,
relapse, or death. OS was defined from the date of initial
chemotherapy to the date of death. Lost to follow-up was
the date of last follow-up. Chi-square and Fisher’s exact
tests were used to identify the CR predictive factors. EFS
and OS were estimated according to the Kaplan-Meier
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rank test. In the multivariate analysis, multiple logistic
regression analysis was conducted for CR, and the Cox
proportional hazard model was performed to assess the
independent prognostic factors for EFS and OS. The SPSS
version 14.0 (SPSS Inc., Chicago, IL, USA) was used for all
statistical analyses, and all tests were two-sided. Statistical
significance was defined as p< 0.05.
RESULTS
Patient characteristics
The clinicopathological characteristics of the 126
patients with stage III/IV DLBCL are listed in Table 1. The
median age at diagnosis was 57 years (range, 16 to 81).
Treatment
In total, 61% of the patients finished six to eight cycles
of R-CHOP. The remaining patients failed to complete
the intended chemotherapy due to progression or relapse
of the disease or because the toxicity of the regimen was
intolerable. Thirteen percent of the patients were treated
with radiotherapy. Radiotherapy was usually used for
treating residual masses that were retained after the full
R-CHOP course had been completed or for palliation of
the symptoms caused by the tumor masses. Patients whose
disease relapsed or progressed after first-line chemotherapy
received salvage chemotherapy with a variety of regimens.
Prognostic factors used in the univariate and
multivariate analyses
With a median follow-up time of 22.4 months (range,
0.5 to 69.3), the CR rate was 69%, the 2-year EFS was
56%, and the 2-year OS was 67.4% in all patients (Fig. 1).
In the univariate analysis, when the extranodal site
number cut-off was set at ≥ 3, the presence of three or
more extranodal sites was significantly associated with
a poor prognosis for CR (p = 0.04), EFS (p = 0.01), and
OS (p < 0.001). Age > 60 years was also significantly
associated with a poor prognosis for EFS (p= 0.03) (Table
2, Fig. 2). When the extranodal site number cut-off was set
at ≥ 2, this variable was no longer significantly associated
with CR (p = 0.08), EFS (p = 0.47), or OS (p = 0.35). In
the multivariate analysis, using the IPI factors but with
the extranodal site cut-off set at ≥ 3, the extranodal site
number remained significantly associated with EFS (p <
0.01; hazard ratio [HR], 2.60; 95% confidence interval
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Figure 1. Survival curves for all patients.
Table 1. Patient clinicopathological characteristics
(n = 126)
Characteristics Number  (%)
Median age, yr (range)  57 (16 - 81) 
Age, stratified 
≤ 60 yr  73 (57.9)
> 60 yr  53 (42.1)
Gender 
Male 64  (50.8)
Female 62  (49.2)
Eastern Cooperative Oncology Group performance status 
1 108  (85.7)
2 to 3  18 (14.3)
Lactate dehydrogenase levels
Normal 28  (22.6)
Elevated 96  (77.4)
Number of extranodal sites 
0 17  (13.5)
1 54  (42.9)
2 33  (26.2)
3 to 5  22 (17.4)
Ann Arbor stage 
III 26  (20.6)
IV 100  (79.4)
Bulky disease 
Yes 10  (7.9)
No 116  (92.1)
Pathology
Diffuse large B-cell lymphoma 116 (92.1)
T-cell/histiocyte-rich large B-cell lymphoma 6 (4.7)
Primary mediastinal B-cell lymphoma 2 (1.6)
Intravascular diffuse large B-cell lymphoma 2 (1.6)
Complete response 
Yes 87 (69.0)
No 39 (31.0)
Relapse or progression 
Yes 33 (26.2)
No 93 (73.8)304 The Korean Journal of Internal Medicine Vol. 25, No. 3, September 2010
Figure 2. Event-free survival and overall survival curves when the patients were stratified according to whether they had (A) < 2 vs. ≥
2 extranodal sites (ENS) or (B) < 3 vs. ≥ 3 ENS. 
A B
Table 2. Univariate analysis of complete response, 2-year event-free survival, and 2-year overall survival in relation
to patient characteristics
Characteristics CR, %  p value  2-yr EFS, %  p value  2-yr OS, %  p value 
Total 69.0  56.3  67.4 
Age, yr  0.85  0.03  0.25 
≤ 60  69.9  64.7  71.5 
> 60  67.9  43.5  62.1 
Gender 0.85  0.6  0.54 
Male 70.3  52.2  69.2 
Female 67.7  60.3 65.6 
ECOG PS  0.45  0.5  0.14 
0 to 1  70.9  56.5  70.5 
2 to 4  60.9  55.2  53.8 
LDH 0.11  0.13  0.09 
Normal 82.1  66.2  78.4 
Elevated 65.6  53.7  64.8 
Number of ENS  0.04  0.01  < 0.001 
< 3  73.1  58.8  72.2 
≥ 3 50.0  47.2  43.3 
Bulky disease  0.72  0.62  0.36 
Yes 60.0  57.1  45.0 
No 69.8  56.8  68.9 
CR, complete response; EFS, event-free survival; OS, overall survival; ECOG PS, Eastern Cooperative Oncology Group performance
status; LDH, lactate dehydrogenase; ENS, extranodal sites.[CI], 1.29 to 5.26) and OS (p < 0.01; HR, 3.52; 95% CI,
1.68 to 7.35). Age > 60 years also remained significantly
associated with a poor EFS (p = 0.02; HR, 1.95; 95% CI,
1.12 to 3.41) (Table 3). 
Outcomes of patients classified according to the
standard IPI and the R-IPI 
To determine the efficacy of the standard IPI, the
patients were stratified into low- (1 IPI factor), intermediate-
(2 to 3 factors), and high-risk (4 to 5 factors) groups. The
three risk groups had a 2-year EFS of 68%, 55%, and 56%
(p = 0.17), respectively, and a 2-year OS of 85%, 68%, and
58% (p = 0.04), respectively (Table 4, Fig. 3). Thus, the
standard IPI was effective for determining the prognosis
of R-CHOP patients with DLBCL for OS but not for EFS. 
To determine the efficacy of the R-IPI, the patients were
regrouped into good- (1 to 2 IPI factors) and poor-prognosis
(3 to 5 factors) groups. It should be noted that the R-IPI
normally includes three risk groups, but only two risk
groups were employed in this study because all of our
patients were stage III and IV patients and could not
belong to a risk group characterized by the absence of IPI
factors. The good- and poor-prognosis groups had a 2-
year EFS of 65% and 50% (p = 0.02), respectively, and a
2-year OS of 76% and 62% (p = 0.04), respectively (Table
4, Fig. 3). Thus, the R-IPI was of good prognostic relevance
for both EFS and OS for R-CHOP-treated patients with
DLBCL.  
Outcomes according to the E-IPI, in which the
extranodal site number cut-off was set at ≥ 3
As indicated above, the number of extranodal sites was
more effective as a prognostic factor when it was stratified
as < 3 and ≥ 3 than when it was stratified as < 2 and ≥ 2.
To assess this further, we modified the IPI by adjusting
the cut-off of the number of extranodal sites so that ≥ 3
extranodal sites indicated a poor prognosis. We refer to
this modified IPI as the extranodal site-modified IPI (E-
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Table 3. Multivariate analysis of complete response, event-free survival, and overall survival 
Indicates complete response  Event-free survival  Overall survival 
Variables HR  (95%  CI)  p value HR  (95%  CI)  p value HR  (95%  CI)  p value 
Age (> 60 yr)  1.16  (0.53 - 2.57)  0.71  1.95  (1.12 - 3.41)  0.02  1.60  (0.86 - 2.99)  0.14 
Elevated LDH  1.93  (0.64 - 5.83)  0.25  1.46  (0.67 - 3.20)  0.35  1.62  (0.62 - 4.27)  0.33 
ECOG PS (> 1)  1.43  (0.54 - 3.82)  0.47  1.29  (0.63 - 2.63)  0.49  1.75  (0.84 - 3.66)  0.14 
Gender (male)  1.13  (0.54 - 3.82)  0.76  0.71  (0.40 - 1.26)  0.25  0.98  (0.52 - 1.86)  0.95 
ENS (≥ 3)  2.46  (0.93 - 6.50)  0.07  2.60  (1.29 - 5.26)  0.01  3.52  (1.68 - 7.35)  0.001 
HR, hazard ratio; CI, confidence interval; LDH, lactate dehydrogenase; ECOG PS, Eastern Cooperative Oncology Group performance
status; ENS, extranodal sites.
Table 4. Event-free survival and overall survival values of R-CHOP-treated patients after classifying them
according to the standard IPI, the R-IPI, and the E-IPI
Risk group  No. of IPI factors Patients, % 2-yr EFS, % p value 2-yr OS, % p value 
IPI  0.17 0.04
Low 1 12.7 68 85
Intermediate  2 - 3 64.3 55 68
High  4 - 5 23.0 56 58
R-IPI  0.02 0.04
Good  1 - 2 40.5 65 76
Poor  3 - 5 59.5 50 62
E-IPI  0.01 0.001
Low 1 12.7 79 86
Intermediate  2 - 3 72.2 56 70
High  4 - 5 15.1 42 39
R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; IPI, international prognostic index; R-IPI, revised
international prognostic index; E-IPI, extranodal site-modified IPI; EFS, event-free survival; OS, overall survival.IPI). Based on the E-IPI, we redivided the patients into
low- (1 IPI factor), intermediate- (2 to 3 IPI factors), and
high-risk (4 to 5 IPI factors) groups (Table 4). The E-IPI
was of good prognostic value for both EFS and OS, as the
2-year EFS values of the low-, intermediate-, and high-risk
groups were 79%, 56%, and 42%, respectively (p = 0.01),
and the 2-year OS values for these groups were 86%,
70%, and 39% (p = 0.001), respectively (Table 4, Fig. 3).
Significantly, unlike the standard IPI and the R-IPI, the
E-IPI identified a group of patients whose survival rates
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Figure 3. Event-free survival and overall survival curves of patients classified according to the standard international prognostic
index (IPI, A), the revised IPI (R-IPI, B), and the extranodal site-modified IPI (E-IPI, C). 
A
B
Cwere below 50%. 
DISCUSSION
Much effort has been expended to define a prognostic
index for DLBCL because pretreatment risk assessment
helps to choose the initial treatment and to predict
outcomes. The IPI is the standard indicator that, until
recently, was generally used in practice and clinical trials
to predict the outcomes of patients with DLBCL. Because
the treatment of choice for patients with DLBCL has
changed from CHOP to R-CHOP, the overall outcomes of
these patients has improved remarkably [2,4]. This
change in standard treatment has led to attempts to
reevaluate the clinical and biological prognostic factors
that were relevant in the CHOP era [12-14,16]. Recently,
two reports showed that the predictive power of IPI was
reduced in patients with R-CHOP-treated DLBCL, and
new prognostic models based on a modification of the
IPI were suggested [14,15]. It is also possible that the
relevance of the prognostic markers varies depending on
the geographic area and patient ethnicity due to varying
baseline clinical characteristics of the patients. Compared
to patients in other countries, Koreans have higher rates of
extranodal involvement in DLBCL, which is one of the five
clinical IPI factors [7-11]. Such geographic and ethnic
variation suggests that Korean patients may differ from
patients of other ethnicities in terms of the degree of
extranodal involvement that is of prognostic significance
[18]. 
Here, we sought to identify the cut-off extranodal site
number that was prognostically relevant for R-CHOP-
treated Korean patients with disseminated DLBCL. The
standard IPI states that ≥ 2 extranodal site indicates a
poor prognosis. Indeed, a recent report showed that R-
CHOP-treated patients with DLBCL in Singapore who had
≥ 2 extranodal sites had a lower CR and 2-year survival
than patients with 0 or 1 extranodal site, although this
variable did not remain significant after a multivariate
analysis [14]. The same study also showed that male
gender and advanced stage were significantly associated
with a poor prognosis. In contrast, in this study on Korean
patients, we found that lymphoma involvement of ≥ 3
extranodal sites was significantly associated with a poor
prognosis for EFS and OS upon both univariate and
multivariate analysis, whereas setting the cut-off rate at ≥
2 was of no prognostic relevance. The disparity between
our study and the Singapore study may relate to the
different prevalences of extranodal site involvement in
Singapore and Korea. In addition, although we also
evaluated the prognostic relevance of other IPI factors for
our Korean patients, only age > 60 years had power to
predict a poor EFS in this cohort. These results support
the notion that the prognostic factors and their power to
predict disease outcome may vary for patients with
DLBCL who differ in geography and ethnicity. Thus, to
predict the prognosis of a specific cohort more precisely,
the individual prognostic factors may need to be modified
and optimized to improve their predictive power. 
For our patients, who had advanced stage DLBCL and
who were treated with R-CHOP, the standard IPI remained
effective as a prognostic model for OS but could not
predict EFS. Similarly, a previous report by a British
Columbia study group showed that the predictive power
of the standard IPI was diminished when used with R-
CHOP-treated patients with DLBCL [15]. As a result,
those authors developed the R-IPI, in which the five IPI
factors are redistributed, and the patients are classified
into very good-, good-, and poor-prognosis groups [15]. In
the present study, we found that the R-IPI had power to
predict both the EFS and OS of our cohort, although it
should be noted that our patients could only be classified
into good- and poor-prognosis groups because we excluded
patients with localized disease so as to achieve treatment
homogeneity. 
Significantly, we found that the E-IPI provided more
relevant information about the prognosis of Korean
patients with DLBCL than did the standard IPI or the
R-IPI. Because the overall prognosis of DLBCL has
improved greatly since the introduction of R-CHOP, it has
become difficult to identify patients who are at higher risk
for a poor prognosis [2,4,15]. Indeed, we found that the
standard IPI and R-IPI failed to identify a high-risk group
of R-CHOP-treated DLBCL patients that had a survival
rate < 50%. This agrees with observations in other studies,
although the present study cannot be compared directly to
previous reports because of the relatively shorter follow-
up period and the inclusion of advanced stage patients
only [14,15]. In contrast, the E-IPI identified a patient
group in our cohort that had a 2-year survival of only 39%.
Although these observations need to be validated by
additional studies performed in other regions and with
different ethnic groups, the E-IPI appears to be promising
for determining the prognosis of Korean DLBCL patients
in the R-CHOP era.
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with regard to patients with DLBCL in general. This is in
part because our sample size was relatively small due to
the exclusion of patients with localized disease so that we
could analyze patients who were treated uniformly.
Moreover, this study was also limited because biologic
markers were not evaluated sufficiently, although there
are few biologic markers for R-CHOP-treated patients
[5,12,16]. Further investigation is needed to determine the
applicability of our observations for different regions and
ethnicities, especially in countries where extranodal site
involvement of DLBCL is more common. 
In conclusion, setting the number of extranodal sites at
< 3 vs. ≥ 3, rather than the original < 2 vs. ≥ 2, was the
most significant prognostic factor for EFS and OS of R-
CHOP-treated Korean patients with stage III/IV DLBCL.
Although the standard IPI, R-IPI, and E-IPI were all
predictive of survival, the E-IPI was clinically more useful
for identifying the high-risk group in this cohort. These
observations must be studied further to determine their
general applicability.  
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